It must be emphasised that only 2.6% of the participants were hospitalised for HF within a month of referral and they had a median NT-proBNP of 587 [138–960] ng/L, so compared to the STRONG-HF trial and the current study, a less complex HF patient group was probably examined. The gene discussed is NPPB; the disease is hydrops fetalis.